Operative Management of Benign and Locally Aggressive Bone Tumors

Introduction to Locally Aggressive Benign Bone Tumors

The surgical management of benign but locally aggressive bone tumors requires a delicate balance between complete oncologic eradication and the preservation of biomechanical function and joint kinematics. The raw literature extensively documents the evolution of treatment for Giant Cell Tumor of Bone (GCTB), Chondroblastoma, Chondromyxoid Fibroma (CMF), and Osteoblastoma. While histologically benign, these lesions exhibit a propensity for aggressive local destruction, cortical breach, and, in rare instances, benign pulmonary metastasis.

This masterclass delineates the evidence-based surgical protocols, biomechanical considerations, and step-by-step operative techniques required to manage these complex lesions. The gold standard for the majority of these tumors remains extended intralesional curettage coupled with local adjuvant therapy and meticulous defect reconstruction.

Giant Cell Tumor of Bone (GCTB)

Giant Cell Tumor of bone is a locally aggressive neoplasm characterized by osteoclast-like multinucleated giant cells. It predominantly affects the meta-epiphyseal region of long bones in skeletally mature individuals, most commonly around the knee (distal femur, proximal tibia), distal radius, and sacrum.

Indications for Surgery

• Campanacci Grade I (Latent): Intralesional curettage.
• Campanacci Grade II (Active): Extended intralesional curettage with local adjuvants and reconstruction (polymethylmethacrylate [PMMA] or bone graft).
• Campanacci Grade III (Aggressive): Extended curettage if joint salvage is possible; en bloc wide resection with endoprosthetic or allograft reconstruction if the joint is destroyed or the tumor is massive.

Clinical Pearl: Approximately 2% to 3% of GCTBs metastasize to the lungs (benign metastasizing GCT). Routine preoperative high-resolution computed tomography (HRCT) of the chest is mandatory for all patients presenting with a primary GCTB.

Preoperative Planning and Positioning

1. Imaging: Plain radiographs, MRI (to assess soft tissue extension and subchondral bone stock), and CT (to evaluate cortical integrity).
2. Biopsy: Core needle biopsy is required to confirm the diagnosis and rule out giant cell-rich osteosarcoma.
3. Neoadjuvant Therapy: Denosumab (a RANKL inhibitor) may be used to downstage Campanacci III lesions, inducing a peripheral neocortex.
4. Positioning: Dependent on the anatomic site. For the distal femur or proximal tibia, the patient is placed supine on a radiolucent table. A sterile tourniquet is applied to achieve a bloodless field, which is critical for identifying residual tumor tissue.

Surgical Warning: While Denosumab hardens the tumor periphery, it can make curettage significantly more difficult. The thickened, gritty neocortex can trap microscopic tumor cells, potentially increasing the risk of local recurrence if extended curettage is not meticulously performed.

Surgical Approach: Extended Intralesional Curettage

The objective is to remove the macroscopic tumor and eradicate microscopic disease in the reactive zone.

1. Exposure: A longitudinal incision is made over the involved bone, utilizing standard extensile approaches (e.g., lateral approach to the distal femur). The biopsy tract must be excised in continuity with the surgical approach.
2. Cortical Window: A large, oval cortical window is created using a drill and osteotomes. The window must be large enough to allow direct visualization of all internal recesses of the tumor cavity.
3. Gross Curettage: Large ring curettes are used to systematically evacuate the gross tumor. The tissue is sent for definitive histopathology.
4. High-Speed Burr (The "Extended" Phase): This is the most critical step. A high-speed spherical burr is used to aggressively remove 2 to 3 mm of the reactive bone lining the cavity. The surgeon must burr down to normal, bleeding cancellous bone, paying special attention to the subchondral plate.
5. Local Adjuvants: To eradicate microscopic disease, chemical or physical adjuvants are applied:
   • Phenol (89%): Applied with cotton applicators for 3 cycles of 1 minute, followed by neutralization with absolute alcohol or saline.
   • Hydrogen Peroxide (3%): Induces oxidative stress and mechanical bubbling to clear debris.
   • Argon Beam Coagulation: Delivers uniform thermal necrosis to the cavity walls.
   • Liquid Nitrogen: Cryotherapy provides deep necrosis but carries a high risk of iatrogenic fracture.
6. Reconstruction: The cavity is thoroughly irrigated. Reconstruction is typically performed using PMMA bone cement.
   • Biomechanics of PMMA: Cement provides immediate structural stability, allowing early weight-bearing. Furthermore, the exothermic reaction of PMMA curing (reaching up to 70°C) provides an additional thermal adjuvant effect.
   • Radiographic Advantage: PMMA is radiopaque. Any future radiolucent line developing between the cement mantle and the host bone is a highly sensitive indicator of local recurrence.
   • Subchondral Grafting: If the subchondral bone plate is extremely thin (<2 mm), a layer of cancellous allograft or autograft is packed against the cartilage before cementation to prevent thermal necrosis of the articular surface.

Postoperative Protocol

• Weight-Bearing: Immediate weight-bearing as tolerated if reconstructed with PMMA and the cortical integrity is robust. If bone grafting or prophylactic internal fixation (plates/screws) was required, partial weight-bearing is maintained for 6 to 8 weeks.
• Surveillance: Radiographs of the operative site and a chest radiograph/CT every 3 months for the first 2 years, then every 6 months up to 5 years.

Chondroblastoma

Chondroblastoma is a rare, benign, cartilage-producing tumor that characteristically arises in the epiphyses or apophyses of long bones in skeletally immature patients (typically 10 to 20 years of age). The proximal humerus, distal femur, and proximal tibia are classic locations.

Indications for Surgery

Due to the risk of progressive joint destruction, physeal arrest, and persistent pain, surgical intervention is universally indicated upon diagnosis.

Surgical Approach and Technique

The surgical challenge in chondroblastoma lies in eradicating the tumor while preserving the adjacent open physis and the overlying articular cartilage.

1. Positioning and Approach: The approach is dictated by the lesion's location. For femoral head lesions, a surgical dislocation or a core decompression approach may be utilized. Recent literature supports the use of arthroscopic-assisted resection for intra-articular or subchondral lesions to minimize morbidity.
2. Trans-metaphyseal vs. Trans-epiphyseal Route:
   • If the physis is open, a trans-metaphyseal approach is preferred if the lesion can be accessed without violating the growth plate.
   • If the lesion is entirely epiphyseal, a careful trans-epiphyseal approach using a small drill hole may be necessary, accepting a small risk of localized physeal arrest.
3. Curettage: Meticulous intralesional curettage is performed. Because the tumor is often adjacent to articular cartilage, aggressive high-speed burring must be done with extreme caution to avoid breaching the joint.
4. Adjuvants: Phenol is generally avoided near the articular cartilage and open physis due to the risk of chemical necrosis. Pulsatile lavage and mechanical burring are the primary methods of extending the curettage.
5. Reconstruction: Unlike GCTB, PMMA is rarely used in chondroblastoma due to the risk of thermal injury to the physis and articular cartilage. The cavity is densely packed with cancellous autograft (e.g., from the iliac crest) or allograft.

Pitfall: Failure to recognize secondary aneurysmal bone cyst (ABC) components, which are present in up to 20% of chondroblastomas, can lead to massive intraoperative hemorrhage. Preoperative MRI is essential to identify fluid-fluid levels indicative of an ABC component.

Postoperative Protocol

• Immobilization: Protected weight-bearing for 6 to 12 weeks to allow for graft incorporation and to prevent subchondral collapse.
• Monitoring: Long-term follow-up is required not only for tumor recurrence (which occurs in 10-15% of cases) but also to monitor for limb-length discrepancies or angular deformities resulting from physeal injury.

Chondromyxoid Fibroma (CMF)

Chondromyxoid fibroma is one of the rarest benign bone tumors, characterized by a lobulated architecture of chondroid, myxoid, and fibrous tissues. It typically presents as an eccentric, metaphyseal lesion in the lower extremities (proximal tibia, distal femur, foot bones) of young adults.

Indications for Surgery

Surgical intervention is indicated to alleviate pain, prevent pathologic fracture, and confirm the diagnosis, as CMF can radiographically and histologically mimic chondrosarcoma.

Surgical Approach and Technique

CMF has a higher recurrence rate than many other benign bone tumors if treated with simple curettage alone (up to 25-30%). Therefore, a more aggressive approach is warranted.

1. En Bloc Resection vs. Extended Curettage:
   • Expendable Bones: For lesions in expendable bones (e.g., proximal fibula, ribs, certain foot bones), en bloc marginal resection is the treatment of choice, reducing the recurrence rate to near zero.
   • Major Long Bones: For lesions in the tibia or femur, extended intralesional curettage is performed.
2. Curettage and Burring: A large cortical window is created. The tumor often has a distinct lobular, bluish-grey appearance. After gross removal, the sclerotic rim must be aggressively burred away. CMF lobules can hide in microscopic cortical scalloping; thus, the burr must reach normal cancellous bone.
3. Adjuvants and Reconstruction: Phenol or argon beam coagulation is highly recommended. The defect is subsequently reconstructed with bone graft or PMMA, depending on the size of the defect and the need for immediate structural support. Prophylactic internal fixation is utilized if the cortical window compromises more than 30% of the bone's diameter.

Clinical Pearl: The histologic differentiation between CMF and low-grade chondrosarcoma can be notoriously difficult. Always ensure the biopsy is reviewed by a specialized musculoskeletal pathologist before proceeding with definitive surgery.

Osteoblastoma

Osteoblastoma is a rare, benign, bone-forming tumor that is histologically identical to an osteoid osteoma but is distinguished by its larger size (greater than 2 cm) and its tendency for progressive growth. It has a strong predilection for the posterior elements of the spine and the metadiaphysis of long bones.

Indications for Surgery

Unlike osteoid osteomas, which may occasionally burn out or respond to NSAIDs, osteoblastomas exhibit progressive local destruction, cause severe pain, and can lead to painful scoliosis or neurologic compromise when located in the spine. Surgery is definitively indicated.

Surgical Approach: Spine vs. Appendicular Skeleton

Spinal Osteoblastoma

1. Preoperative Embolization: Spinal osteoblastomas are highly vascular. Preoperative selective arterial embolization within 24 to 48 hours of surgery is strongly recommended to minimize intraoperative blood loss.
2. Surgical Excision: The goal is complete marginal excision. Intralesional curettage in the spine carries a high recurrence rate and risks epidural tumor seeding.
3. Decompression and Stabilization: If the tumor involves the pedicle or lamina and causes canal stenosis, a wide laminectomy/facetectomy is performed. Because this often destabilizes the spinal segment, concomitant posterior spinal instrumentation and fusion (using pedicle screws and rods) are usually required.

Appendicular Osteoblastoma

1. Exposure: Standard longitudinal approaches are used. The tumor is often surrounded by a dense rim of reactive sclerosis and marked periosteal reaction.
2. Resection Strategy:
   • Intralesional Excision: For large metaphyseal lesions, aggressive intralesional curettage with a high-speed burr is performed. The nidus is highly vascular and gritty.
   • Marginal Resection: If the lesion is diaphyseal and cortical, an en bloc marginal resection (removing the tumor with a cuff of normal bone) is preferred to guarantee complete removal and prevent recurrence.
3. Reconstruction: Defects are grafted with autograft or allograft. Structural allografts and plate fixation are necessary if a segmental or large cortical resection is performed.

Surgical Warning: A rare variant known as "Aggressive Osteoblastoma" exhibits epithelioid osteoblasts and has a higher propensity for local recurrence and borderline malignant behavior. If this variant is identified on biopsy, wide en bloc resection is mandatory, treating the lesion akin to a low-grade osteosarcoma.

Postoperative Protocol

• Spinal Lesions: Patients are mobilized early with a rigid orthosis (TLSO or cervical collar) depending on the level of fusion. Serial neurologic examinations are critical in the immediate postoperative period.
• Appendicular Lesions: Rehabilitation is dictated by the method of reconstruction. Protected weight-bearing is maintained until radiographic evidence of graft incorporation and cortical consolidation is observed, typically at 3 to 6 months.

Conclusion

The operative management of benign and locally aggressive bone tumors demands a rigorous, evidence-based approach. The surgeon must master the techniques of extended intralesional curettage, the judicious application of chemical and thermal adjuvants, and the biomechanical principles of defect reconstruction. Whether managing a giant cell tumor of the distal femur, a chondroblastoma threatening a pediatric physis, a recurrent chondromyxoid fibroma, or a vascular osteoblastoma of the spine, adherence to these strict oncologic and reconstructive principles is paramount to achieving local control, preserving joint function, and optimizing patient outcomes.